tetano
Editor, Senior Moderator
Sci Adv
. 2023 Jun 23;9(25):eabo4100.
doi: 10.1126/sciadv.abo4100. Epub 2023 Jun 23. A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus
Zhenzhen Wang[SUP] 1 2 [/SUP], Zhenhua Li[SUP] 1 2 [/SUP], Weiwei Shi[SUP] 1 2 [/SUP], Dashuai Zhu[SUP] 1 2 [/SUP], Shiqi Hu[SUP] 1 2 [/SUP], Phuong-Uyen C Dinh[SUP] 1 2 [/SUP], Ke Cheng[SUP] 1 2 3 [/SUP]
Affiliations
The circulating flu viruses merging with the ongoing COVID-19 pandemic raises a more severe threat that promotes the infectivity of SARS-CoV-2 associated with higher mortality rates. Here, we conjugated recombinant receptor binding domain (RBD) of SARS-CoV-2 spike protein onto inactivated influenza A virus (Flu) to develop a SARS-CoV-2 virus-like particle (VLP) vaccine with two-hit protection. This double-hit vaccine (Flu-RBD) not only induced protective immunities against SARS-CoV-2 but also remained functional as a flu vaccine. The Flu core improved the retention and distribution of Flu-RBD vaccine in the draining lymph nodes, with enhanced immunogenicity. In a hamster model of live SARS-CoV-2 infection, two doses of Flu-RBD efficiently protected animals against viral infection. Furthermore, Flu-RBD VLP elicited a strong neutralization activity against both SARS-CoV-2 Delta pseudovirus and wild-type influenza A H1N1 inactivated virus in mice. Overall, the Flu-RBD VLP vaccine is a promising candidate for combating COVID-19, influenza A, and coinfection.
. 2023 Jun 23;9(25):eabo4100.
doi: 10.1126/sciadv.abo4100. Epub 2023 Jun 23. A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus
Zhenzhen Wang[SUP] 1 2 [/SUP], Zhenhua Li[SUP] 1 2 [/SUP], Weiwei Shi[SUP] 1 2 [/SUP], Dashuai Zhu[SUP] 1 2 [/SUP], Shiqi Hu[SUP] 1 2 [/SUP], Phuong-Uyen C Dinh[SUP] 1 2 [/SUP], Ke Cheng[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 37352360
- DOI: 10.1126/sciadv.abo4100
The circulating flu viruses merging with the ongoing COVID-19 pandemic raises a more severe threat that promotes the infectivity of SARS-CoV-2 associated with higher mortality rates. Here, we conjugated recombinant receptor binding domain (RBD) of SARS-CoV-2 spike protein onto inactivated influenza A virus (Flu) to develop a SARS-CoV-2 virus-like particle (VLP) vaccine with two-hit protection. This double-hit vaccine (Flu-RBD) not only induced protective immunities against SARS-CoV-2 but also remained functional as a flu vaccine. The Flu core improved the retention and distribution of Flu-RBD vaccine in the draining lymph nodes, with enhanced immunogenicity. In a hamster model of live SARS-CoV-2 infection, two doses of Flu-RBD efficiently protected animals against viral infection. Furthermore, Flu-RBD VLP elicited a strong neutralization activity against both SARS-CoV-2 Delta pseudovirus and wild-type influenza A H1N1 inactivated virus in mice. Overall, the Flu-RBD VLP vaccine is a promising candidate for combating COVID-19, influenza A, and coinfection.